Stakeholder engagement in the development of an upper extremity outcome measure for children with rare musculoskeletal conditions.
Outcome measure development
Rare musculoskeletal condition
Stakeholder engagement
Upper extremity
Journal
Research involvement and engagement
ISSN: 2056-7529
Titre abrégé: Res Involv Engagem
Pays: England
ID NLM: 101708164
Informations de publication
Date de publication:
08 Aug 2023
08 Aug 2023
Historique:
received:
10
05
2023
accepted:
28
07
2023
medline:
9
8
2023
pubmed:
9
8
2023
entrez:
8
8
2023
Statut:
epublish
Résumé
Upper extremity (UE) involvement is prevalent in 73% of individuals with arthrogryposis multiplex congenita (AMC), yet no AMC-specific outcome measure exists. When developing a measure specific to a population with a rare musculoskeletal condition, clinicians' and patients' perspectives and involvement is a crucial and necessary step. This study sought to determine the most clinically useful items for an outcome measure of UE function for children with AMC as defined by caregivers and clinicians. To ensure the perspectives and needs of caregivers of children with AMC and clinicians were considered in the development of the UE measure for AMC, a Nominal Group technique (NGT) with caregivers of children with AMC (phase 1) followed by a three-round survey with clinicians (phase 2) were carried out. Phase 1: Eleven individuals participated in the nominal group technique and identified 32 items. The most important items were Picking up an object (n = 11), Eating (n = 10), Reaching mouth (n = 10), Getting out of bed (n = 10). Phase 2: Invitations to participate to an online survey was sent to 47 experts in the field of AMC, 20 participants completed round 1, 15 completed round 2 and 13 completed round 3. Throughout the survey, participants were asked about movement required to screen the UE, essential domains to be included in the measure, establishing a scoring guide and identifying tasks associated with joint motion and position. A preliminary version of an UE AMC-specific outcome measure was developed with the help of caregivers' perspectives and expert opinions. Arthrogryposis multiplex congenita (AMC) is a rare musculoskeletal condition affects the joints and muscles of the body. In about 70% of the cases, it affects the upper extremities (UE). However, there is no specific outcome measure for UE function in children with AMC. An outcome measure refers to a tool or method used to assess and measure the results or effects of a particular treatment, intervention, or condition. It helps healthcare professionals and researchers understand the impact or outcome of a specific situation, such as the level of improvement or changes in a person's health or function. The goal of this study was to develop such a measure while accounting for the perspectives of youth with AMC, their caregivers and clinicians. To achieve this, a study was conducted in two phases. In the first phase, a Nominal Group technique (NGT) was used to gather input from caregivers of children with AMC. Eleven individuals participated and identified 32 items, with the most important being picking up an object, eating, reaching the mouth, and getting out of bed. In the second phase, a three-round survey was sent to 47 experts in the field of AMC, with 20 participants completing the first round, 15 completing the second round, and 13 completing the third round. The survey asked participants about screening UE movement, essential domains to include in the measure, establishing a scoring guide, and identifying tasks associated with joint motion and position. With the help of caregivers’ perspectives and expert opinions, a preliminary version of an UE AMC-specific outcome measure was developed. This measure will be useful in assessing the UE function in children with AMC and will aid clinicians in developing appropriate treatment plans for this rare condition.
Sections du résumé
BACKGROUND
BACKGROUND
Upper extremity (UE) involvement is prevalent in 73% of individuals with arthrogryposis multiplex congenita (AMC), yet no AMC-specific outcome measure exists. When developing a measure specific to a population with a rare musculoskeletal condition, clinicians' and patients' perspectives and involvement is a crucial and necessary step. This study sought to determine the most clinically useful items for an outcome measure of UE function for children with AMC as defined by caregivers and clinicians.
METHODS
METHODS
To ensure the perspectives and needs of caregivers of children with AMC and clinicians were considered in the development of the UE measure for AMC, a Nominal Group technique (NGT) with caregivers of children with AMC (phase 1) followed by a three-round survey with clinicians (phase 2) were carried out.
RESULTS
RESULTS
Phase 1: Eleven individuals participated in the nominal group technique and identified 32 items. The most important items were Picking up an object (n = 11), Eating (n = 10), Reaching mouth (n = 10), Getting out of bed (n = 10). Phase 2: Invitations to participate to an online survey was sent to 47 experts in the field of AMC, 20 participants completed round 1, 15 completed round 2 and 13 completed round 3. Throughout the survey, participants were asked about movement required to screen the UE, essential domains to be included in the measure, establishing a scoring guide and identifying tasks associated with joint motion and position.
CONCLUSION
CONCLUSIONS
A preliminary version of an UE AMC-specific outcome measure was developed with the help of caregivers' perspectives and expert opinions.
Arthrogryposis multiplex congenita (AMC) is a rare musculoskeletal condition affects the joints and muscles of the body. In about 70% of the cases, it affects the upper extremities (UE). However, there is no specific outcome measure for UE function in children with AMC. An outcome measure refers to a tool or method used to assess and measure the results or effects of a particular treatment, intervention, or condition. It helps healthcare professionals and researchers understand the impact or outcome of a specific situation, such as the level of improvement or changes in a person's health or function. The goal of this study was to develop such a measure while accounting for the perspectives of youth with AMC, their caregivers and clinicians. To achieve this, a study was conducted in two phases. In the first phase, a Nominal Group technique (NGT) was used to gather input from caregivers of children with AMC. Eleven individuals participated and identified 32 items, with the most important being picking up an object, eating, reaching the mouth, and getting out of bed. In the second phase, a three-round survey was sent to 47 experts in the field of AMC, with 20 participants completing the first round, 15 completing the second round, and 13 completing the third round. The survey asked participants about screening UE movement, essential domains to include in the measure, establishing a scoring guide, and identifying tasks associated with joint motion and position. With the help of caregivers’ perspectives and expert opinions, a preliminary version of an UE AMC-specific outcome measure was developed. This measure will be useful in assessing the UE function in children with AMC and will aid clinicians in developing appropriate treatment plans for this rare condition.
Autres résumés
Type: plain-language-summary
(eng)
Arthrogryposis multiplex congenita (AMC) is a rare musculoskeletal condition affects the joints and muscles of the body. In about 70% of the cases, it affects the upper extremities (UE). However, there is no specific outcome measure for UE function in children with AMC. An outcome measure refers to a tool or method used to assess and measure the results or effects of a particular treatment, intervention, or condition. It helps healthcare professionals and researchers understand the impact or outcome of a specific situation, such as the level of improvement or changes in a person's health or function. The goal of this study was to develop such a measure while accounting for the perspectives of youth with AMC, their caregivers and clinicians. To achieve this, a study was conducted in two phases. In the first phase, a Nominal Group technique (NGT) was used to gather input from caregivers of children with AMC. Eleven individuals participated and identified 32 items, with the most important being picking up an object, eating, reaching the mouth, and getting out of bed. In the second phase, a three-round survey was sent to 47 experts in the field of AMC, with 20 participants completing the first round, 15 completing the second round, and 13 completing the third round. The survey asked participants about screening UE movement, essential domains to include in the measure, establishing a scoring guide, and identifying tasks associated with joint motion and position. With the help of caregivers’ perspectives and expert opinions, a preliminary version of an UE AMC-specific outcome measure was developed. This measure will be useful in assessing the UE function in children with AMC and will aid clinicians in developing appropriate treatment plans for this rare condition.
Identifiants
pubmed: 37553603
doi: 10.1186/s40900-023-00479-6
pii: 10.1186/s40900-023-00479-6
pmc: PMC10408044
doi:
Types de publication
Journal Article
Langues
eng
Pagination
64Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Rheumatol. 2011 Aug;38(8):1716-9
pubmed: 21807791
Res Involv Engagem. 2018 Sep 10;4:28
pubmed: 30214822
Am J Med Genet C Semin Med Genet. 2019 Sep;181(3):385-392
pubmed: 31397084
Phys Occup Ther Pediatr. 2020;40(6):610-636
pubmed: 32299279
J Hand Ther. 2003 Jan-Mar;16(1):12-21
pubmed: 12611441
Semin Plast Surg. 2016 Feb;30(1):5-13
pubmed: 26869858
Am J Med Genet A. 2013 Apr;161A(4):737-44
pubmed: 23444103
J Med Imaging Radiat Sci. 2016 Dec;47(4):290-293
pubmed: 31047251
J Pediatr Orthop. 2020 Aug;40(7):357-360
pubmed: 32040062
Am J Med Genet C Semin Med Genet. 2019 Sep;181(3):363-371
pubmed: 31268234
Health Res Policy Syst. 2018 Feb 7;16(1):5
pubmed: 29415734
Health Technol Assess. 1998;2(14):i-iv, 1-74
pubmed: 9812244
Eur J Med Genet. 2014 Aug;57(8):464-72
pubmed: 24704792
J Rehabil Med. 2010 Feb;42(2):170-8
pubmed: 20140414
Disabil Rehabil. 2020 Aug;42(16):2318-2324
pubmed: 30741031
Int J Clin Pharm. 2016 Jun;38(3):655-62
pubmed: 26846316
Res Involv Engagem. 2021 Sep 14;7(1):66
pubmed: 34521478
Am J Med Genet A. 2015 Jun;167(6):1193-5
pubmed: 25847824
Am J Med Genet C Semin Med Genet. 2019 Sep;181(3):372-384
pubmed: 31479584
J Rehabil Med. 2011 Nov;43(11):987-96
pubmed: 22031344
Am J Med Genet C Semin Med Genet. 2019 Sep;181(3):280-287
pubmed: 31452331